非布司他联合依托考昔治疗痛风性关节炎的临床疗效分析  

Analysis of clinical efficacy of febuxostat combined with etoricoxib in the treatment of gouty arthritis

作　　者：何冶 洪明志 朱小春[1] Ye HE;Ming-Zhi HONG;Xiao-Chun ZHU(Department of Rheumatology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325035,Zhejiang Province,China;Department of Rheumatology,Taizhou Municipal Hospital,Taizhou 318000,Zhejiang Province,China;Department of Burn and Plastic Surgery,Taizhou Municipal Hospital,Taizhou 318000,Zhejiang Province,China)

机构地区：[1]温州医科大学附属第一医院风湿免疫科,浙江温州325035 [2]台州市立医院风湿免疫科,浙江台州318000 [3]台州市立医院烧伤美容整形科,浙江台州318000

出　　处：《数理医药学杂志》2023年第6期446-451,共6页Journal of Mathematical Medicine

摘　　要：目的 分析非布司他联合依托考昔治疗痛风性关节炎(gouty arthritis, GA)的临床疗效。方法 选取2020年4月至2022年9月温州医科大学附属第一医院收治的180例GA患者作为研究对象,将患者分为对照组、观察组,每组90例。对照组采用依托考昔治疗,观察组采用非布司他联合依托考昔治疗。为期1周的疗程结束后,比较两组患者的临床疗效、疼痛程度、尿酸(uric acid, UA)、红细胞沉降率(erythrocyte sedimentation rate, ESR)、C反应蛋白(C reactive protein, CRP)指标及不良反应。结果 一周后,观察组患者痛风性关节炎临床疗效评价有效率高于对照组(96.67%vs. 66.67%,P <0.001);两组患者视觉疼痛模拟评分(visual pain simulation score, VAS)均下降,观察组显著低于对照组(1.18±0.58 vs. 2.67±0.92,P <0.001);两组患者尿酸、血沉、C反应蛋白指标均下降,观察组显著低于对照组(P <0.001);两组患者药物相关不良反应发生率比较,差异无统计学意义(23.33%vs. 18.89%,P=0.363)。结论 非布司他联合依托考昔治疗痛风性关节炎有助于改善临床疗效。Objective To investigate the clinical efficacy of febuxostat combined with etoricoxib regimen in the treatment of gouty arthritis(GA).Methods A total of 180 patients with GA admitted to The First Affiliated Hospital of Wenzhou Medical University from April 2020 to September 2022 were included as the analysis subjects,and the patients were divided into control group and observation group,with 90 cases in each group.The control group was treated with etoricoxib,and the observation group was treated with febuxostat combined with etoricoxib.After a one-week course of treatment,the two groups of GA patients were compared in terms of clinical efficacy,pain degree,uric acid(UA),erythrocyte sedimentation rate(ESR),C reactive protein(CRP)indexes and adverse reactions.Results The clinical efficacy evaluation of gouty arthritis in the observation group was higher than that in the control group(96.67%vs.66.67%,P<0.001).The visual pain simulation score(VAS)decreased in both groups,and the score of patients in the observation group was significantly lower than that in the control group(1.18±0.58 vs.2.67±0.92,P<0.001).UA,ESR and CRP indexes decreased in both groups,and the indexes of patients in the observation group were significantly lower than those in the control group(P<0.001).There was no significant difference of drug-related adverse reactions between the two groups(23.33%vs.18.89%,P=0.363).Conclusion Febuxostat combined with etoricoxib has a significant effect in patients with gouty arthritis.

关 键 词：痛风性关节炎 非布司他 依托考昔 临床疗效 不良反应 

分 类 号：R589.7[医药卫生—内分泌]